We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.
1 / 3 
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Learn More
We are led by experienced biopharma executives with exceptional track records of building strong companies, delivering innovative treatments and growing diverse teams.
Learn MoreGuided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.
Patients dosed with izokibep
Dedicated professionals
Growth financing committed
Clinical-stage programs
We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.
Immune-focused drugmaker has raised more than $550 million in venture capital.
Any biotech that can rake in half a billion dollars from investors in 12 months is clearly doing something right.
Unique IL-17A inhibitor demonstrated notable dose-dependent improvements in sleep, pain and function in patients with psoriatic arthritis.